PMS Assessing the Long-term Efficacy and Safety of Nevirapine Therapy (Combined With Other ARV Drugs) in HIV-1 Positive Patients in Daily Clinical Practice.
- Conditions
- HIV Infections
- First Posted Date
- 2008-08-18
- Last Posted Date
- 2014-03-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 280
- Registration Number
- NCT00736502
- Locations
- 🇵🇱
Boehringer Ingelheim Investigational Site 12, Kraków, Poland
🇦🇹Boehringer Ingelheim Investigational Site 3, Salzburg, Austria
🇦🇹Boehringer Ingelheim Investigational Site 1, Graz, Austria
Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2008-08-18
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 510
- Registration Number
- NCT00737100
- Locations
- 🇺🇸
205.339.021 Boehringer Ingelheim Investigational Site, Miami, Florida, United States
🇺🇸205.339.024 Boehringer Ingelheim Investigational Site, Cleveland, Ohio, United States
🇺🇸205.339.022 Boehringer Ingelheim Investigational Site, Indianapolis, Indiana, United States
Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: linagliptine 5 mgDrug: linagliptine 5 mg and pioglitazone 30 mg
- First Posted Date
- 2008-08-15
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2122
- Registration Number
- NCT00736099
- Locations
- 🇺🇸
1218.40.10010 Boehringer Ingelheim Investigational Site, Hollywood, Florida, United States
🇺🇸1218.40.10018 Boehringer Ingelheim Investigational Site, Houston, Texas, United States
🇬🇷1218.40.30007 Boehringer Ingelheim Investigational Site, Athens, Greece
Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors
- Conditions
- Neoplasms
- Interventions
- Drug: BIBW 2992Drug: BIBF 1120
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2009-08-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 28
- Registration Number
- NCT00730821
- Locations
- 🇺🇸
1239.1.1 Boehringer Ingelheim Investigational Site, Tampa, Florida, United States
🇺🇸1239.1.2 Boehringer Ingelheim Investigational Site, Detroit, Michigan, United States
🇺🇸1239.1.3 Boehringer Ingelheim Investigational Site, Scottsdale, Arizona, United States
Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Drug: BIBW2992Drug: BIBW2992 + paclitaxel
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2014-03-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 41
- Registration Number
- NCT00730925
- Locations
- 🇧🇪
1200.41.32003 Boehringer Ingelheim Investigational Site, Antwerpen, Belgium
🇧🇪1200.41.32006 Boehringer Ingelheim Investigational Site, Namur, Belgium
🇧🇪1200.41.32007 Boehringer Ingelheim Investigational Site, Charleroi, Belgium
BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma
- First Posted Date
- 2008-08-04
- Last Posted Date
- 2017-08-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 151
- Registration Number
- NCT00727506
- Locations
- 🇺🇸
1200.36.0007 Boehringer Ingelheim Investigational Site, Charleston, South Carolina, United States
🇨🇦1200.36.1011 Boehringer Ingelheim Investigational Site, Halifax, Nova Scotia, Canada
🇨🇦1200.36.1010 Boehringer Ingelheim Investigational Site, Winnipeg, Manitoba, Canada
Safety and Efficacy of 4-weeks Treatment of BIBW 2948 BS in Patients With Chronic Obstructive Bronchitis
- Conditions
- Pulmonary Disease, Chronic ObstructiveBronchitis, Chronic
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2014-03-27
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT00726479
- Locations
- 🇺🇸
1219.4.01004 Boehringer Ingelheim Investigational Site, Spartanburg, South Carolina, United States
🇫🇷1219.4.3306B Boehringer Ingelheim Investigational Site, Bethune Cedex, France
🇫🇷1219.4.3303A Boehringer Ingelheim Investigational Site, Montpellier, France
Sifrol (Pramipexole) Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary Restless Legs Syndrome
- Conditions
- Restless Legs Syndrome
- First Posted Date
- 2008-07-24
- Last Posted Date
- 2014-06-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 549
- Registration Number
- NCT00721279
- Locations
- 🇦🇹
Boehringer Ingelheim Investigational Site, Zirl, Austria
Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: BI 1744 CL plus tiotropium bromideDevice: Respimat® Inhaler
- First Posted Date
- 2008-07-22
- Last Posted Date
- 2015-08-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 141
- Registration Number
- NCT00720499
- Locations
- 🇧🇪
1237.9.03253 Boehringer Ingelheim Investigational Site, Brussel, Belgium
🇧🇪1237.9.03254 Boehringer Ingelheim Investigational Site, Edegem, Belgium
🇧🇪1237.9.03252 Boehringer Ingelheim Investigational Site, Leuven, Belgium
Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours
- Conditions
- Neoplasms
- Interventions
- Drug: BIBW 2992
- First Posted Date
- 2008-07-16
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 47
- Registration Number
- NCT00716417
- Locations
- 🇧🇪
1200.37.3202 Boehringer Ingelheim Investigational Site, Bruxelles, Belgium
🇧🇪1200.37.3201 Boehringer Ingelheim Investigational Site, Edegem, Belgium
🇧🇪1200.37.3203 Boehringer Ingelheim Investigational Site, Gent, Belgium